Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2019-08-14 Interim / Quarterly Rep…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
Datum:14.08.2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'STADA-Zwischenbericht 1. Halbjahr 2019' (Interim Report 1st Half 2019). It contains comprehensive financial statements, including consolidated income statements, balance sheet data, and detailed management analysis of financial performance (EBITDA, revenue, margins) for the first half of the fiscal year. It is not an announcement of a report, but the report itself, containing substantive financial data. Therefore, it is classified as an Interim/Quarterly Report. H1 2019
2019-08-14 German
Report Publication Announcement 2019
Report Publication Announcement Classification · 100% confidence The document is very short (1592 characters) and explicitly states that it is a 'Preliminary announcement of the publication of financial reports'. It details *when* and *where* the actual 'Financial report of the group (half-year/Q2)' will be disclosed (August 14, 2019) and provides links to where the final report will be located. According to Rule 2 (The 'MENU VS MEAL' Rule), a document announcing the publication of another report, especially when short, should be classified as a Report Publication Announcement (RPA). The content is purely administrative regarding the release schedule of the H1/Q2 report, not the report itself.
2019-08-07 English
Hinweis auf Halbjahresfinanzbericht vom 01.01.2019 bis zum 30.06.2019
Report Publication Announcement Classification · 100% confidence The document is a short notification (784 characters) announcing the availability of a half-year financial report. It provides a link to the report rather than containing the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2019-08-07 German
Datum:07.08.2019
Report Publication Announcement Classification · 100% confidence The document is a short notification (763 characters) that informs stakeholders about the availability of the company's half-year financial report. It provides a link to the report and specifies the publication date. According to the 'Menu vs Meal' rule, since this is a short announcement regarding the publication of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2019-08-07 German
STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer
Capital/Financing Update Classification · 99% confidence The document is titled "STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer" and details the outcome of an offer to purchase outstanding 1.750% Notes due 2022. This involves a corporate action related to debt restructuring or financing, specifically the results of a tender offer for bonds. This activity falls under corporate financing or capital structure changes. The closest matching category is 'Capital/Financing Update' (CAP). It is not a standard annual report (10-K), earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing transaction.
2019-06-21 English
Upcoming Expiration of Tender Offer and Intention to Delist Notes
Capital/Financing Update Classification · 99% confidence The document is a news release from STADA Arzneimittel AG regarding the upcoming expiration of a tender offer for its outstanding 1.750% Notes due 2022 and the company's intention to apply for the delisting of these Notes from the Luxembourg Stock Exchange. This announcement concerns a corporate action related to debt instruments (Notes) and the subsequent removal from trading, which directly impacts the company's capital structure and financing arrangements. While it mentions delisting, the primary focus is on the tender offer mechanics and the intention to delist, which falls under financing/capital structure changes. The most fitting category is 'Capital/Financing Update' (CAP), as it details the conclusion of a debt tender offer and subsequent delisting intention. It is not a formal delisting announcement (DLST) yet, but a precursor related to financing terms. It is also not a general regulatory filing (RNS) because it fits the specific CAP category better.
2019-05-23 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.